The study assessed the ABHR preferences of HCWs in a randomized crossover design. The formulation chosen for the intervention was Saniswiss Sanitizer Hands H1, which was compared either to Hopirub® or Hopigel® which were the ABHR formulations that the HCWs were using during their work at the time of the study. Hopirub® and Hopigel® are isopropanol-based and also contain chlorhexidine digluconate, while H1 is ethanol-based. H1 contains superfatting agents as the humectant, while Hopigel® and Hopirub® contain isopropyl myristate and bisabolol. All formulations passed the EN1500 standards and are used in healthcare settings.
Forty two HCWs from seven wards in the HUG Beau Séjour site (183-bed hospital) participated, and data collection occurred from August 1st to September 15th, 2021. The study design consisted of two consecutive 7 to10-day intervention periods (Fig. 1). The intervention periods were personalized to each participant, and average estimated intervention days were based on individual HCW schedules. Participants were randomized to one of two sequences of formulations; either the ABHR that they were using previously followed by H1 or vice versa. As healthcare workers were already using the control ABHR every day in their work, there was no washout period between interventions. All formulations were prepared in identical bottles with only the coded labels differing; though participants were blinded to the contents of the bottle, they were accustomed to using either Hopirub® or Hopigel®, so it was likely that the majority of them were able to correctly identify which formulation they were testing.
The data collection forms for tolerability and acceptability were adapted from the WHO “Protocol for Evaluation and Comparison of Tolerability and Acceptability of Different Alcohol-based Handrubs: Method 2”.5 HCW participation was voluntary and participants were included if their employment was 70% at minimum. HCWs were only allowed to participate if they had less than three weeks of vacation during the study period, and were using either Hopirub® or Hopigel®.
An informed consent form was given to each participant containing the information necessary to make a decision regarding their participation in the study. Each participant was informed that their participation in the study was voluntary and that they could withdraw at any time. Confidentiality was guaranteed by the use of participant identification code numbers corresponding to the previously determined randomization list.
Individual appointments were made with all participants to take baseline measurements and distribute the bottles of ABHR. Skin type was determined by color in accordance with the WHO protocol.5 Researchers collected participant data including: ward, sex, age, number of years of experience and estimated frequency of ABHR use. Baseline evaluations collected additional participant data including: skin color, activities that might impact skin condition, hand cream use and history of dermatitis. HCWs used pocket-sized 100mL bottles filled with the test formulations instead of the typical pocket-sized bottles that are used at HUG since 1995.23 After a 7 to 10-day intervention period, researchers met with each HCW for the follow up evaluation and semi-structured interview (Appendix: Assessment of tolerability to alcohol-based handrubs, translated from French). If the end of the first intervention coincided with the beginning of the second intervention, the first follow-up and the second baseline coincided. If the HCW was on vacation between the two intervention phases, the second baseline evaluation was performed upon their return to work.
The primary outcome was to assess whether the differences in acceptability and the polarization of preferences observed in the laboratory study22 would be replicated in a clinical setting. The secondary outcome was the difference in skin tolerability from baseline. To evaluate acceptability, participants gave feedback on the test formulation’s qualities of color, smell, texture, stickiness, presence of deposits or threads, irritation, drying effect, ease of use, speed of drying, application, and overall evaluation. Acceptability, participant preference and any additional feedback was collected in a short semi-structured interview after each intervention.
For the secondary outcome, tolerability was measured by two methods: assessment by a trained observer and self-assessment by the HCW. Observers evaluated HCWs’ skin for redness, scaliness and fissures. Redness ranged from 0–4, scaliness from 0–5 and fissures from 0–3, zero being an absence of symptoms and the increasing numbers relating to the increasing severity of symptoms. Participants self-reported their skin condition from 0–4 for the following elements: appearance, integrity, hydration level and sensations (Appendix).
Tolerability measurements were taken at baseline and after the interventions (Figure). Intention-to-treat population was used for the analyses including all participants randomized having completed at least one of the intervention periods, meaning that the population studied included 37 participants. Descriptive statistics reported mean standard deviation (SD) or median and interquartile range [IQR] as appropriate. Estimated intervention differences were assessed between the intervention (H1) and control (Hopirub® or Hopigel®) with 95% confidence intervals (CIs). The comparisons between interventions used paired t-tests. To assess the robustness of the analyses to the normality assumptions, non-parametric Wilcoxon signed-rank tests were applied. No correction for multiplicity was used. All statistical analyses were performed using R version 3.6.3 or greater.
This study did not fall within the framework of the human research act of the 30 September 2011 (HRA, SR 810.30), but concerned care practices already in use at HUG, so no approval by the ethics committee was needed. The approval for the study was the responsibility of the Academic Council of HUG. Participation was voluntary and all participants signed informed consent forms. All participant data was kept confidential and anonymized before use. The data is property of University of Geneva Hospitals and Faculty of Medicine.